ArticlePublic health weekly report2026
Evolution and Future Directions of the National Measles Immunization Program in the Republic of Korea.
Article in Public health weekly report, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Measles is a highly contagious airborne disease capable of rapid transmission in healthcare and school settings when immunity gaps accumulate. This review aims to examine the evolution of the measles immunization program in the Republic of Korea (ROK) and analyzes policy implications through international comparison. Methods: This narrative review uses the Korea Disease Control and Prevention Agency guidelines, national statistics, 2018-2019 outbreak reports, World Health Organization and United Nations Children's Fund coverage estimates, and official guidelines and reports from the United States, the United Kingdom, Japan, and Canada. The comparison is based on four criteria: the two-dose schedule, coverage, school-entry verification, and outbreak response. Results: ROK strengthened measles control through routine measles-mumps-rubella vaccination, the measles-rubella catch-up campaign in 2001, and a mandatory school-entry verification system. The 2018-2019 import-related outbreaks were contained through rapid reporting, laboratory confirmation, contact management, and targeted vaccination. From 2015 to 2024, first-dose coverage remained at 97.3-97.9% and second-dose coverage ranged from 94.6-97.8%. International comparison showed that the ROK maintained a high two-dose coverage and a stable school-entry verification system, while regional immunity gaps persisted in some countries. Conclusions: High two-dose coverage and school-entry verification have resulted in the elimination of measles in the ROK. Continued management of susceptible populations and policy evaluation using internationally comparable indicators remain important.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.